Abstract:

To detect the serum human kallikrein 10 (hk10) expression in patients with ovarian cancer and control groups，and investigate the clinical significance of hk10 in the diagnosis of ovarian cancer. Methods Enzyme-linked immunoassay （ELISA）mothod was used to detect the hk10 levels in serum in ovarian cancer group(n=50),benign ovarian tumor group(n=20),benign gynecological disease (higher CA125 values,n=26),other malignant gynecological cancer group(n=18) and healthy controls(n=36). Results The level of serum hk10 in the ovarian cancer group was(15.60±9.23) μg.L^-1 and the positive rate was 88.89%,in benign ovarian tumor group they were(6.60±2.65) μg.L^-1 and 10.00%;in other malignant gynecological cancer group they were(6.11±2.42) μg?L-1 and 11.11%,in healthy control group they were(6.00±2.26) μg.L^-1 and 11.11%，the level of serum hk10 and the positive rate in ovarian cancer group were higher than those in other groups(P<0.01).The level of serum hk10 and the positive rate in stage Ⅲ/Ⅳ ovarian cancer group were(18.29±9.74) μg?L-1 and 94.44%,they were significantly higher than those in stage Ⅰ / Ⅱ ovarian cancer group(9.87 μg?L-1±4.04 μg.L^-1 and 75.00%)(P<0.01).The level of serum hK10 in patients with ovarian cancer after operation was (13.83±1.56)  μg.L^-1 which was lower than before operation.Conclusion The serum hk10 level is significantly increased in ovarian cancer group,its specificity was higher than CA125. hk10 is expected to become a new marker in ovarian cancer.

Key words: human kallikrein 10;ovarian neoplasm;CA125